1) La descarga del recurso depende de la página de origen
2) Para poder descargar el recurso, es necesario ser usuario registrado en Universia

Opción 1: Descargar recurso

Detalles del recurso


Menopause is the permanent cessation of menstruation resulting from the loss of ovarian follicular activity. It is estimated that perhaps 50 million women worldwide will go into menopause annually. Atherosclerotic cardiovascular disease, osteoporotic fractures and Alzheimer's dementia are common chronic disorders after menopause, representing major health problems in most developed countries. Apart from being influenced by environmental factors, these chronic disorders recognize a strong genetic component, and there are now considerable clinic evidences that these disorders are related to low hormonal milieu of postmenopausal women. Here, we review up-to-date available data suggesting that genetic variation may contribute to higher susceptibility to four sporadic chronic syndromes such as osteoporosis (OP), osteoarthritis (OA), Alzheimer's disease (AD) and coronary artery disease (CAD). For these four syndromes candidate genes that today appear as major loci in genetic susceptibility encode for proteins specific of a given system, as the vitamin D receptor (VDR) gene for the skeleton and, therefore, OP or angiotensin converting enzyme (ACE) for the cardiovascular system and, therefore, CAD. The investigation of gene polymorphisms in various pathological conditions typical of postmenopause offer an explanation not only of their genetic inheritance but also of their co-segregation in given individuals. In this view, it may be possible to identify a common set of genes whose variants contribute to a common genetic background for these different disorders. Ideal candidates appear genes of the estrogen response cascade [i.e. estrogen receptor (ERs), enzymes involved in estrogen metabolism or co-activators and co-inhibitors]. All together this information may represent the basis both for future recognition of individuals at risk and for the pharmacogenetic driving of drug responsiveness.

Pertenece a

ORBi Open Repository and Bibliography  


Massart, François [author] -  REGINSTER, Jean -  Yves [author] -  Brandi, M L [author] - 

Id.: 55285926

Idioma: inglés  - 

Versión: 1.0

Estado: Final

Palabras claveAlzheimer Disease/genetics - 

Cobertura:  international - 

Tipo de recurso: info:eu-repo/semantics/article  - 

Tipo de Interactividad: Expositivo

Nivel de Interactividad: muy bajo

Audiencia: Estudiante  -  Profesor  -  Autor  - 

Estructura: Atomic

Coste: no

Copyright: sí

Requerimientos técnicos:  Browser: Any - 

Relación: [References] Maturitas
[References] Maturitas

Fecha de contribución: 08-may-2012


* 40
* 2
* 103-16
* 0378-5122

Otros recursos del mismo autor(es)

  1. Vitamin D inadequacy in Belgian postmenopausal osteoporotic women



    Inadequate serum vitamin D [25(OH)D] concentrations are associa...

  2. Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis



    The efficacy, safety and tolerability of lumiracoxib, a novel s...

  3. Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system



    Symptomatic slow-acting drugs (SYSADOA) have been largely studi...

  4. Secular increase in the incidence of hip fractures in Belgium between 1984 and 1996: need for a concerted public health strategy OBJECTIVE: To determine the incidence of hip fractures (at the proximal end of the femur) in Belgium...
  5. Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty International audience

Otros recursos de la mismacolección

No existen otros recursos

Aviso de cookies: Usamos cookies propias y de terceros para mejorar nuestros servicios, para análisis estadístico y para mostrarle publicidad. Si continua navegando consideramos que acepta su uso en los términos establecidos en la Política de cookies.